The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:F1000Res
Prif Awduron: Chakraborty, Sandeep, Rendón-Ramírez, Adela, Ásgeirsson, Bjarni, Dutta, Mouparna, Ghosh, Anindya S., Oda, Masataka, Venkatramani, Ravindra, Rao, Basuthkar J., Dandekar, Abhaya M., Goñi, Félix M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: F1000Research 2015
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4309170/
https://ncbi.nlm.nih.gov/pubmed/25671081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.2-286.v3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg